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INHIBITION OF THE IN VITRO CLEARING ACTIVITY OF PANCREATIC
LIPASE BY HYPERLIPEMIC AND HYPERCHOLESTEREMIC
SERUM AND BY TISSUE EXTRACTS *
EDMUND KLEIN, M.D.,t WALTER F. LEVER, M.D.,t BRONIUS BASKYS, PH.1)J
AND DEWEY M. DUCKETT, JR., B.S.t
In previous communications (1, 2) we have
reported that the serum of patients with primary
idiopathic hyperlipemia and of patients with sec-
ondary hyperlipemia markedly inhibits heparin-
induced clearing factor activity. The anti-
clearing factor activity of hvperlipemie serum is
considerably greater than the anti-clearing factor
activity of normal serum, which had been demon-
strated by Hollett and Meng (3), or that of serum
of patients with hypereholesteremia (1). We
subsequently reported (4, 5) that inhibitors of
clearing factor activity were widely distributed
in human and other mammalian tissues obtained
from individuals without known disturbance of
lipid transport.
In order to determine whether the inhibitors
of clearing factor activity present in normal tis-
sues and in the serum of patients with hyper-
lipemia were also active against other lipolytie
agents, their in vitro effects on pancreatic lipase
were examined. In the course of these studies,
inhibitors of pancreatic lipase were found in the
serum of patients with primary and secondary
hyperlipemia as well as in the serum of patients
with primary hypereholesteremia. Inhibitors of
pancreatic lipase were also found to be widely
distributed in normal mammalian tissues.
METHOO5 ANO MATERIALS
Serum was obtained and prepared as previously
described (2). Tissuet extracts were prepared by
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extraction with a glyeine buffer liy a modification
(5) of the method of Schneider (6).
The test system was similar to that previously
used (2, 5) and contained 0.4 cc of normal fasting
serum, 0.3 cc of standard fat emulsion and 0.5 cc
of a suspension of pancreatic lipase.) To this
mixture was added 0.7 cc of the test material
(i.e., hyperlipemie serum, hypercholesteremie
serum, tissue extract) or normal serum, saline or
glyeine as control. All components were kept at
—30° C. or, in the presence of lipoproteins, at
4° C. until used. The lipase suspension was added
last and immediately thereafter the mixtures were
incubated at 37° C.
Paper eleetrophoresis was carried out on ali-
quots of the mixtures as described by Rerbst,
Lever and Rurley (7) in order to determine the
effects of lipase and its inhibitors on the eleetro-
phoretie inobilities of the serum a- and$-lipopro-
teins. Optical density determinations on the
incubation mixtures were carried out by a modifi-
cation (2, 5) of the method of Grossman (8).
RESULTS
Inhibition of the in vitro activity of pancreatic
lipase by serum of patients wit/i idiopathic and
secondary hypertipemia. The serum of 6 patients
with idiopithie hyperlipemia markedly inhibited
pancreatic lipase activity (Table I). Anti-lipase
activity was present also in the serum of the 6
patients with secondary hyperlipemia tested,
The Society for Investigative Dermatology, Inc.,
Atlantic City, N. J. June 6, 1959.
t Post-mortem specimens were obtained from
the Department of Pathology at the Massa-
chusetts General Hospital through the cooperation
of Dr. B. Castleman.§ The standard fat emulsion was obtained
through the courtesy of Dr. J. Lawson, The Up-john Company, Kalamazoo, Michigan. It con-
tained 15% eoeoanut oil and was diluted 30 fold
prior to use.
The lipase suspension was prepared by sus-
pending 30 mg. of pancreatic lipase (Sigma Chemi-
cal Corp.) in 10 cc of normal saline. This prepa-
ration was diluted with serum of normal fasting
individuals between 3—10 times. The lipase/serum
mixture was so adjusted that in the test system
described a clearing activity of hetween 40—50
units (optical density) was obtained on incubation
at 37°C for 60 minutes.
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TABLE I
Inhibition of pancreatic lipase by serum of patients
with idiopathic hypertipemia
Total
Patient Fatty
Acids
tog %
M. E. 2340
M. P. 1248
J. S. 2070
R. V. 4208
H. L. 1863
M. C. 824
(two patients with diabetes mellitus, one patient
with glycogen storage disease, and three patients
with Neimann-Piek's disease*).
Inhibition of the in eitro activity of pancreatic
lipase by serum of patients with primary hypercho-
lesteremia. The serum of patients with primary
hypereholesteremie xanthomatosis inhibited pan-
creatic lipase (Figure 1). Inhibition of pancreatic
lipase was noted whether or not clinical signs of
hypercholestcremia (i.e., cutancons or cardio-
vascular manifestations) were present (Fignre 2).
Anti-lipase activity was, furthermore, observed
in 5 out of 8 normocholesteremic individuals who
were first degree relatives (siblings, parents or
direct descendants) of patients with primary
hypercholesteremia (Figure 3).
Anti-lipase activity was not found in the serum
of 14 patients with secondary hypcrcholesteremia
(hypothyroidism, hypogonadism, biliary cirrho-
sis). On the contrary, the serum of three of the
five patients with biliary cirrhosis studied not
only failed to inhibit pancreatic lipase, but con-
tained a lipolytic activity which rapidly cleared
a mixture of standard fat emulsion with normal
serum.
Inhibition of in vitro activity of pancreatic tipase
by tissue extracts. Extracts of human tissues in-
hibited pancreatic lipase to varying degrees,
depending on the type of tissue (Figure 4). Ex-
tracts of liver and of spleen contained the highest
anti-lipase activities, and extracts of whole skin
and aorta the lowest. Extracts of heart and
kidney showed an intermediate degree of anti-
lipolytic activity.
Comparison of the anti-lipolytic actieities ob-
served in the serum of patients with xant hornet oses
and in the spteen extract. The inhibitors of pan-
creatic lipase in human spleen, in the serum of
patients with hyperbpemia and in the serum of
patients with primary hypercholesteremic xan-
thomatosis were found to be different from each
other on the basis of some of their physical
chemical characteristics (Table II). Anti-lipasc
activity in the spleen extract was stable to heat-
ing at 100° C for 30 minutes, while no anti-lipase
activities could be demonstrated in liyperlipcmic
serum or hypercholesteremic serum after heat-
ing. The anti-lipase activity of hypcrlipemic
serum, furthermore, was found to be extractable
with ether, while the ether extracts of hypercho-
lesteremic serum or of spleen did not contain
anti-lipolytic activities. It was further noted
that the anti-lipase activity of hyperlipemic
serum was insoluble at low ionic strength while
the inhibitory activities of the spleen extract and
of the hypercholestcremic serum remained in
solution after prolonged dialysis (48 hours)
against distilled water (Table II).
Comparison of the effects of hypertipemic and
hypercholesteremic serum, respectively, on clearing
factor and pancreatic lipase. Serum of patients
with idiopathic hyperlipcmia inhibited beparin-
induced clearing factor, pancreatic lipase and the
lipolytic activity of the serum of patients with
biliary cirrhosis (Table 111).
The serum of patients with primary hypercho-
lesteremic xanthomatosis inhibited pancreatic
bpase (40-100%), had no effects on heparin-
induced clearing factor, and either had no effect
or activated (20—40%) the lipolytic activities of
serum in biliary cirrhosis. Taurocholate acti-
vated pancreatic lipase (25—30%) and inhibited
clearing factor (30—70%) as well as the lipolytic
General Hospital through the cooperation of Dr.
Charles Du Toit and Miss 0. Margaret O'Rourke.)
A solution of 1.6% sodium tauroeholeate in
physiological saline.
Chol.
tog %
658
452
696
604
518
342
P'li0ida
tog %
421
385
348
817
642
312
% Inhibi-
tion of OD
Changes
100
100
82—95
100
100
53—72
* The serum specimens of patients with Nei-
mann-Pick's disease were ohtained from Dr. Allen
Crocker and Dr. Sidney Farber of the Children's
Cancer Research Foundation, Boston, Massa-
chusetts.
f In order to estahlish if this lipolytic activity
was specific for serum of patients with hyper-
eholesteremia secondary to biliary cirrhosis,
randomly selected samples of serum were tested.
Lipolytic activity was found in approximately 40
per cent of 120 patients with hepatie diseases(portal cirrhosis, acute hepatitis, secondary
malignant disease). Lipolytie activity was also
found in the serum of 10 per cent of 177 patients
with various other pathological states. (These
serum specimens were obtained from the Clinical
Chemistry Lahoratory of the Massachusetts
INHIBITION OF CLEARING ACTIVITY OF PANCREATIC LIPASE
THE EFFECTS OF PLASMA OF PATIENTS WITH PRIMARY
HYPERCHOLIESTERMIC XANTHOMATOSIS IN VITRO ON THE
CLEARING ACTIVITY OF PANCREATIC LIPASE
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FIG. 1
THE EFFECTS OF PLASMA OF PATIENTS WITH PRIMARY
HYPERCHOLESTERMIC WITHOUT CLINICAL SIGNS IN VITRO
ON THE CLEARING ACTIVITY OF PANCREATIC LIPASE
Fia. 2
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activity of serum in biliary cirrhosis (30—100%) mobilities of the lipoproteins were not altered by
(Table III). addition of serum from patients with hyper-
Electrophoretic studies. The velocities of dcc- lipemia or with primary hypercholesteremic
trophoretic migration of the serum a- and xanthomatosis. Tissue extracts, also, had no
-lipoproteins were found to he increased in the apparent effects cii the lipase-induced increase
presence of pancreatic lipase. These increased in the mobilities of the serum lipoproteins.
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THE EFFECTS OF PLASMA OF NORMOCHOLESTEREMIC RELATIVES
OF PATIENTS WITH PRIMARY HYPERCHOLESTERMIC IN VITRO ON
THE CLEARING ACTIVITY OF PANCREATIC LIPASE
FIG. 3
THE EFFECTS OF EXTRACTS OF TISSUES IN VITRO ON THE
CLEARING ACTIVITY OF PANCREATIC LIPASE
DISCUSSION
rfhe degree of inhibition of panCrCatic lipase by
the serum of idiopathic and secondary hyper-
lipemia paralleled the anti-clearing factor activi-
ties of the serum in each of the 12 patients
stndicd. Hyperlipcmic serum, furthermore, in-
hibited the circulating lipolytic agent in biliary
cirrhosis. Thus, multiple anti-lipcdytic activities
are demonstrable in the serum of idiopathic and
secondary hyperlipemia.
A similar relationship was found between the
antilipolytie activities of the various tissues ex-
amined. Tissues such as whole skin and aorta
which, as previously found (5), have the lowest
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TABLE II
Differences between anti -tipot ytic activities in
narmat spteen extract, hypertipemic serum
and hyperchotesteremic serum
Normal
Roman
SpleenExtract
Serum of Pa-
tients with
Idiopathic
Hyperlipemia
Serum of Pa-
tieots with
Primary
Iypercho-xt-
fosis
Heat Stable Unstable Unstable
Ether extract. . . Absent Present Absent
Distilled H20. . . Soluble Insoluble Soluble
TABLE III
Difference in the effects of serum of patients with
idiopathic hypertipemia or primary hypercho-
testeremia and of taurochoteate on the lipotytic
activities exerted by pancreatic tipase, cteariny
factor and serum of patients with hitiary cirrhosis
—, inhibition; +, activation; 0, no effect.
Serum of
Patiee,ts
Lipolytic Activities wit athi'°
lipemia
Serum of Pa-
tieots with
Primary
Hypercho-
lesteremia
vauro-
rho-
leate
Pancreatic lipase
Clearing factor
Serum in biliary
cirrhosis
—
—
—
—
0
0
+
—
—
levels of anti-clearing factor activities, also pre-
sented low levels of inhibition of pancreatic
lipase activity. Spleen and liver, which had high
levels of inhibition of clearing factor activity
(4, 5), also had high levels of inhibition of pan-
creatic lipase activity.
In the serum of patients with primary hvper-
cholcsteremia inhibition of pancreatic lipasc
activity was present without the other abnormal
anti-lipolytic activities. This inhibition was
found not only in the serum of patients with ele-
vated serum cholesterol—irrespective of the
presence or absence of cutaneous or cardiovascu-
lar lesions—but also in first degree relatives of
these patients (agnates and cognates) who had
normal serum cholesterol values. These findings
may suggest that the familial pattern of primary
hypcrcholcstcremia is more adequately reflected
by the presence of inhibition of pancreatic lipasc
activity in the serum than by blood cholesterol
levels. It is possible, however, that the presence
of this inhibition in the serum of normocho-
lcstcrcmic relatives of patients with primary
hypercholcstcremic xanthomatosis merely pre-
cedes an eventual rise of the blood cholesterol
level.
Hyperlipcmic and hypercholcsteremic serum
as well as tissue extracts, although they inhibited
the clearing reaction, failed to reverse the ac-
celeration of the clectrophorctic migration of the
lipoproteins induced by pancreatic lipase. This
is analogous to the failure of byperlipcmic plasma
to reverse the clcctrophoretic changes produced
by clearing factor, while the clearing reaction
itself is inhibited (1). As Lever et at. (7) have
pointed out, electrophoretic determinations rep-
resctit a very sensitive index of lipolytic activity.
The lipolytic activity fonnd in the serum of
some patients with biliary cirrhosis occurs with
high frequency in diseases of the liver but is not
specific for them since it was found also in other
pathological states. This lipolytic activity is ap-
parcntlv different from that exerted by pan-
creatic lipase or clearing factor since hyper-
lipemic serum, hypcrcholcsteremic serum anfl
taurocholate respectively have different effects on
the lipolytic activities of serum in biliary cirrhosis,
of pancreatic lipase and of clearing factor.
sUMMARy
The in vitro clearing activity of pancreatic
lipase was found to be inhibited 1) by the serum
of patients with idiopathic and secondary hypcr-
lipemia, 2) by the serum of patients with primary
hypcrcholestcrctnia and some of their norma-
cholesteremic relatives and 3) by extracts of a
number of tissues obtained from individuals with-
out known disturbance of lipid transport.
rrhe serum of patients with hypercholesteremia
secondary to hypothyroidism, to hypogonadism
and to biliary cirrhosis did not inhibit the clearing
activity of pancreatic lipase.
The inhibitory activities of hyperlipemic serum,
of hypercholcsteremic serum and of spleen ex-
tract were shown to be different from each other.
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